摘要
目的 观察伊立替康(CPr-11)联合顺铂(DDP)治疗复发晚期小细胞肺癌的疗效及安全性.方法 选择复发晚期小细胞肺癌患者29例,给予CPT-11 80 mg·m-2,静脉滴注,第1、8天;DDP 75 mg·m-2,静脉滴注,第2天至第5天；28 d为1个周期.化学治疗前常规给予抗呕吐治疗；化学治疗期间给予水化利尿及对症支持治疗.至少2个周期化学治疗后评价疗效.结果 29例中,完全缓解2例(6.9％),部分缓解9例(31.0％),稳定10例(34.5％),病情进展8例(27.6％),总有效率为37.9％.中位生存期7.4个月.主要不良反应:白细胞减少27例(93.1％),血小板减少15例(51.7％),恶心、呕吐19例(65.4％),迟发性腹泻19例(65.4％).无毒性相关死亡病例.结论 CPT-11联合DDP二线治疗复发晚期小细胞肺癌有效率较高,毒副作用可以耐受.
Abstract
Objective To evaluate the efficacy and safety of the irinotecan( CPT-11) combined with cisplatin( DDP) for recrudescent advanced small cell lung cancer (SCLC) patients. Methods 29 patients with recnidescent advanced SCLC were selected. The patients were treated with CPT-11 80 mg · m-2 on the first day and the eighth day by intravenous drip,and cisplatin 75 mg · m-2 from the second day to the fifth day by intravenous drip,a cycle was 28 days. Conventional treatment to against nausea and vomiting was given before chemotherapy jhydration diuresis and supporting therapy were given during the period of chemotherapy. Curative effect was evaluated after chemotherapy at least for two cycles. Results In 29 evaluable patients, response including 2 (6. 9% ) cases were complete remissions and 9 ( 31. 0% ) cases were partial remission, 10 (34.5%) patients had stable disease and 8 ( 27.6% ) had progressive disease, the total effective rate was 37.9%. The median survival time was 7.4 months. The main toxicity reaction was leucopenia( 93.1 % ), thrombocytopenia( 51.7%), nausea and vomin'ng(65.4% ) and tardive diarrhea(65.4%). Non-toxic related death was found in the 29 cases. Conclusion The effective rate of irinotecan combined with cisplatin as second-line therapy treated for recrudescent advanced SCLC is highly active and the toxic reaction can be tolerated.
NETL
NSTL
维普
万方数据